Patent · US Active

Compounds which modulate the CB2 receptor

US7928123B2 · kind B2 · utility

24Cited by

31References

8Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Angela Berry · Gaylordsville, US
Pier Francesco Cirillo · Woodbury, US
Doris Riether · Biberach an der Riß, DE
David Thomson · Ridgefield, US
Renee M. Zindell · New Milford, US
Nigel James Blumire · Biggenden, AU
Chandana CHOWDHURY · Manchester, GB
Monika Ermann · Wantage, GB
James Edward Jenkins · Hungerford, GB
Innocent Mushi · Felton, GB
Christopher Francis Palmer · Abingdon, GB
Malcolm Taylor · Biggenden, AU

Key dates

Filing date	Sep 13, 2007
Grant date	Apr 19, 2011
Priority date	—
Expiry date	May 8, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of formula (I)are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.